6J Biotechnology is a biopharmaceutical company dedicated to the development of innovative anti-cancer metastasis and antiviral drugs. Currently, we already developed a new generation of small molecule compounds 6J-1/6J-2, which are the first class of drugs to effectively suppress cancer metastasis. The 6J-1/6J-2 are under application for the FDA's IND clinical approval. Meanwhile, we also have 6J-3/6J-4, which are drugs target positive-sense single-stranded RNA virus. The antiviral effect of 6J-3/6J-4 has been validated on MERS and the new coronavirus-2019-nCoV and will start clinical trials soon.
The founding team of 6J Biotechnology is composed of Academician, professors, and Ph. Ds from Tsinghua University, Peking University, City University of Hong Kong, Cornell University, Columbia University, and Johns Hopkins University. They not only possess strong academic backgrounds, publishing many research articles but also have extensive experience as senior scientists in pharmaceutical companies in the United States and successfully led two drugs to obtain FDA approval for marketing.
Our Mission
Perform innovative R&D to revolutionize global anti-cancer drug development, and develop efficient and personalized anti-metastasis drugs for cancer patients worldwide.
Our Vision
Become the first company to develop the original anti-metastasis drug for the benefit of global cancer patients.
